Auransa

Auransa Inc. is a clinical-stage, AI-native biopharmaceutical company based in Palo Alto, California, founded in 2014 by Pek Lum. Auransa uses its proprietary SMarTR Engine — a hypothesis-free machine learning platform that mines human disease data such as RNA transcriptome and gene-expression profiles — to discover novel small-molecule therapeutics without starting from a predefined drug target. The company has analyzed more than 500,000 gene-expression profiles across roughly 70 diseases to identify molecular disease subtypes and match them to candidate compounds. Its lead program, AU-409, is a first-in-human Phase 1 candidate for liver cancer (hepatocellular carcinoma), with additional pipeline work in heart-safe chemotherapy and other oncology indications. Auransa is a DCVC / DCVC Bio portfolio company, also backed by Lux Capital, 11.2 Capital, and Harmonix Fund. Auransa is a private drug-discovery company and does not publish a public API, developer portal, or SDK; this profile captures its identity and web presence in the API Evangelist network.

Auransa is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Drug Discovery, and Artificial Intelligence.

Auransa’s developer surface includes support and 5 more developer resources.

🌐 Visit website 📡 Source on GitHub

8.4/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechnologyPharmaceuticalsDrug DiscoveryArtificial IntelligenceMachine LearningOncologyLife SciencesHealthcare

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 8.4/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.9 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/auransa: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Company 2

The organization behind the API

Website

Website

LinkedIn

Other 2

Properties that don't map to a standard resource type

Platform

Platform

Publications

Publications

Source (apis.yml)

aid: auransa
name: Auransa
description: Auransa Inc. is a clinical-stage, AI-native biopharmaceutical company based in Palo Alto, California, founded
  in 2014 by Pek Lum. Auransa uses its proprietary SMarTR Engine — a hypothesis-free machine learning platform that mines
  human disease data such as RNA transcriptome and gene-expression profiles — to discover novel small-molecule therapeutics
  without starting from a predefined drug target. The company has analyzed more than 500,000 gene-expression profiles across
  roughly 70 diseases to identify molecular disease subtypes and match them to candidate compounds. Its lead program, AU-409,
  is a first-in-human Phase 1 candidate for liver cancer (hepatocellular carcinoma), with additional pipeline work in heart-safe
  chemotherapy and other oncology indications. Auransa is a DCVC / DCVC Bio portfolio company, also backed by Lux Capital,
  11.2 Capital, and Harmonix Fund. Auransa is a private drug-discovery company and does not publish a public API, developer
  portal, or SDK; this profile captures its identity and web presence in the API Evangelist network.
url: https://raw.githubusercontent.com/api-evangelist/auransa/refs/heads/main/apis.yml
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: http://static1.squarespace.com/static/64b88de4e311714cd215bed7/t/64cd18e9d05cd663af914d3b/1690553917421/Auransa.jpg?format=1500w
x-type: company
x-source: vc-portfolio
x-backed-by:
- dcvc
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Drug Discovery
- Artificial Intelligence
- Machine Learning
- Oncology
- Life Sciences
- Healthcare
apis: []
common:
- type: DomainSecurity
  url: security/auransa-domain-security.yml
- type: Website
  url: https://www.auransa.com/
- type: Platform
  url: https://www.auransa.com/platform
- type: Support
  url: https://www.auransa.com/contact
- type: Publications
  url: https://www.auransa.com/publications
- type: LinkedIn
  url: https://www.linkedin.com/company/auransa
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence